Lipocine (LPCN) Long-Term Investments (2015 - 2021)

Lipocine's (LPCN) quarterly Long-Term Investments came in at $2.0 million in Q4 2021, down 56.13% on a QoQ basis from $4.6 million in Q1 2021.

Lipocine (LPCN) Long-Term Investments (2015 - 2021) Analysis & Trends

Lipocine (LPCN) has 2 years of Long-Term Investments data on file, last reported at $2.0 million in Q4 2021.

Quarterly Long-Term Investments changed N/A year-over-year to $2.0 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $2.0 million (changed N/A YoY) and the FY2021 annual result came in at $2.0 million, changed N/A from the prior year.
Long-Term Investments declined to $2.0 million in Q4 2021, from $4.6 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $4.6 million in Q1 2021 to a low of $2.0 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	Lipocine	11.15 Mn	-12.76 Mn	-	-

Download Data